Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | CALCRL | Q16602 | 11/20 | 0.51 |
| ▸ | RAMP1 | O60894 | 5/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2872824 | 0.93 | BRD4 (0.56) | BRD4CREBBPCALCRLRAMP1CHRM4 | |
| SCHEMBL3279615 | 0.87 | BRD4 (0.50) | BRD4CREBBPCALCRLRAMP1CHRM4 | |
| SCHEMBL31184539 | 0.87 | BRD4 (0.50) | BRD4CREBBPCALCRLRAMP1CHRM4 | |
| SCHEMBL2100919 | 0.87 | BRD4 (0.50) | BRD4CREBBPCALCRLRAMP1CHRM4 | |
| SCHEMBL31184549 | 0.87 | BRD4 (0.50) | BRD4CREBBPCALCRLRAMP1CHRM4 | |
| Hydrochloric Acid SCHEMBL1812169 | 0.86 | BRD4 (0.49) | BRD4CREBBPCALCRLRAMP1CHRM4 | |
| SCHEMBL13313600 | 0.86 | BRD4 (0.57) | BRD4CREBBPCALCRLRAMP1CHRM4 | |
| SCHEMBL12400687 | 0.84 | CHRM4 (0.50) | BRD4CREBBPCALCRLRAMP1CHRM4 | |
| SCHEMBL16313925 | 0.84 | MAPT (0.47) | BRD4CREBBPCALCRLRAMP1OPRM1 | |
| SCHEMBL5695088 | 0.83 | CALCRL (0.49) | BRD4CREBBPCALCRLRAMP1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | BRD4 2766/4885CREBBP 4343/4885CALCRL 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.